Tenaya Therapeutics Inc (TNYA) - Total Assets
Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) holds total assets worth $104.98 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tenaya Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of Tenaya Therapeutics Inc for the company's overall valuation and market capitalisation.
Tenaya Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tenaya Therapeutics Inc's total assets of $104.98 Million consist of 56.2% current assets and 43.8% non-current assets. Review Tenaya Therapeutics Inc (TNYA) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See TNYA stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tenaya Therapeutics Inc's current assets represent 56.2% of total assets in 2024, a decrease from 73.0% in 2019.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2024, down from 62.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tenaya Therapeutics Inc Competitors by Total Assets
Key competitors of Tenaya Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Tenaya Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.64 | 5.27 | 25.78 |
| Quick Ratio | 4.64 | 5.27 | 25.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $48.03 Million | $69.15 Million | $124.92 Million |
Tenaya Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tenaya Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.72 |
| Latest Market Cap to Assets Ratio | 1.14 |
| Asset Growth Rate (YoY) | -29.7% |
| Total Assets | $119.94 Million |
| Market Capitalization | $136.66 Million USD |
Valuation Analysis
Above Book Valuation: The market values Tenaya Therapeutics Inc's assets above their book value (1.14x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Tenaya Therapeutics Inc's assets decreased by 29.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Tenaya Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $119.94 Million | -29.66% |
| 2023-12-31 | $170.51 Million | -38.87% |
| 2022-12-31 | $278.94 Million | -11.91% |
| 2021-12-31 | $316.65 Million | +113.72% |
| 2020-12-31 | $148.16 Million | +289.89% |
| 2019-12-31 | $38.00 Million | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more